Form 8-K - Current report:
SEC Accession No. 0001193125-25-065511
Filing Date
2025-03-27
Accepted
2025-03-27 16:10:44
Documents
15
Period of Report
2025-03-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d943685d8k.htm   iXBRL 8-K 25569
2 EX-99.1 d943685dex991.htm EX-99.1 59174
6 GRAPHIC g943685g0325192701732.jpg GRAPHIC 2957
  Complete submission text file 0001193125-25-065511.txt   223105

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ikt-20250327.xsd EX-101.SCH 2857
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikt-20250327_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikt-20250327_pre.xml EX-101.PRE 11713
17 EXTRACTED XBRL INSTANCE DOCUMENT d943685d8k_htm.xml XML 3768
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39676 | Film No.: 25779371
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)